171 related articles for article (PubMed ID: 36362153)
21. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.
Okano J ; Rustgi AK
J Biol Chem; 2001 Jun; 276(22):19555-64. PubMed ID: 11278851
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of in vitro and in vivo ovarian cancer cell growth by pinoresinol occurs by way of inducing autophagy, inhibition of cell invasion, loss of mitochondrial membrane potential and inhibition Ras/MEK/ERK signalling pathway.
Ning Y; Fu YL; Zhang QH; Zhang C; Chen Y
J BUON; 2019; 24(2):709-714. PubMed ID: 31128027
[TBL] [Abstract][Full Text] [Related]
23. Delineation of gastric tumors with activated ERK/MAPK signaling cascades for the development of targeted therapeutics.
Pandian J; Ganesan K
Exp Cell Res; 2022 Jan; 410(1):112956. PubMed ID: 34864005
[TBL] [Abstract][Full Text] [Related]
24. Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.
Kubota Y; Fujioka Y; Patil A; Takagi Y; Matsubara D; Iijima M; Momose I; Naka R; Nakai K; Noda NN; Takekawa M
Nat Commun; 2022 Jul; 13(1):4063. PubMed ID: 35831322
[TBL] [Abstract][Full Text] [Related]
25. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.
Liu S; Zou Q; Chen JP; Yao X; Guan P; Liang W; Deng P; Lai X; Yin J; Chen J; Chen R; Yu Z; Xiao R; Sun Y; Hong JH; Liu H; Lu H; Chen J; Bei JX; Koh J; Chan JY; Wang B; Kang T; Yu Q; Teh BT; Liu J; Xiong Y; Tan J
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464356
[TBL] [Abstract][Full Text] [Related]
26. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
27. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation.
Steinmetz R; Wagoner HA; Zeng P; Hammond JR; Hannon TS; Meyers JL; Pescovitz OH
Mol Endocrinol; 2004 Oct; 18(10):2570-82. PubMed ID: 15243131
[TBL] [Abstract][Full Text] [Related]
28. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
30. Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
Nokin MJ; Bellier J; Durieux F; Peulen O; Rademaker G; Gabriel M; Monseur C; Charloteaux B; Verbeke L; van Laere S; Roncarati P; Herfs M; Lambert C; Scheijen J; Schalkwijk C; Colige A; Caers J; Delvenne P; Turtoi A; Castronovo V; Bellahcène A
Breast Cancer Res; 2019 Jan; 21(1):11. PubMed ID: 30674353
[TBL] [Abstract][Full Text] [Related]
31. Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms.
Lotz K; Kellner T; Heitmann M; Nazarenko I; Noske A; Malek A; Gontarewicz A; Schäfer R; Sers C
Int J Cancer; 2005 Oct; 116(6):894-902. PubMed ID: 15856468
[TBL] [Abstract][Full Text] [Related]
32. Activation of the MEK-S6 pathway in high-grade ovarian cancers.
Ventura AP; Radhakrishnan S; Green A; Rajaram SK; Allen AN; O'Briant K; Schummer M; Karlan B; Urban N; Tewari M; Drescher C; Knudsen BS
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):499-508. PubMed ID: 20661131
[TBL] [Abstract][Full Text] [Related]
33. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
34. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
35. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
36. Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
Brant R; Sharpe A; Liptrot T; Dry JR; Harrington EA; Barrett JC; Whalley N; Womack C; Smith P; Hodgson DR
Clin Cancer Res; 2017 Mar; 23(6):1471-1480. PubMed ID: 27733477
[No Abstract] [Full Text] [Related]
37. LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway.
Liu J; Hu HB; Liu YM; Li FX; Zhang LP; Liao ZM
Mol Med Rep; 2020 Nov; 22(5):3667-3676. PubMed ID: 33000231
[TBL] [Abstract][Full Text] [Related]
38. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
[TBL] [Abstract][Full Text] [Related]
39. Long non‑coding RNA BANCR promotes proliferation, invasion and migration in esophageal squamous cell carcinoma cells via the Raf/MEK/ERK signaling pathway.
Yu X; Huang M; Yang G
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880577
[TBL] [Abstract][Full Text] [Related]
40. Stepwise activation of p63 and the MEK/ERK pathway induces the expression of ARL4C to promote oral squamous cell carcinoma cell proliferation.
Alkhatib DZR; Thi Kim Truong T; Fujii S; Hasegawa K; Nagano R; Tajiri Y; Kiyoshima T
Pathol Res Pract; 2023 Jun; 246():154493. PubMed ID: 37141698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
